|
Hydroxychloroquine Clinical Trials
10 actively recruiting trials across 5 locations
No change since May 2026
Also known as: HCQ, Plaquenil
Pipeline
Phase 2: 4Phase 3: 2Phase 4: 1Phase 1/2: 2Phase 2/3: 1
Top Sponsors
- VA Office of Research and Development1
- University of Nebraska1
- Tongji Hospital1
- Ravi Amaravadi, MD1
- Qilu Hospital of Shandong University1
Indications
- Cancer5
- Arthritis3
- Inflammatory Cardiomyopathy1
- Liver Disease1
- Refractory Urothelial Carcinoma1
Other3 trials
Philadelphia, Pennsylvania3 trials
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Abramson Cancer Center at University of Pennsylvania
Phase 1/2
ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer
Abramson Cancer Center of the University of Pennsylvania
Phase 2
Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Phase 1/2
Los Angeles, California1 trial
Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
University of California, Los Angeles
Phase 3
Chicago, Illinois1 trial
Omaha, Nebraska1 trial
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
University of Nebraska Medical Center
Phase 3
Charleston, South Carolina1 trial
Autophagy Maintenance (AUTOMAIN)
Medical University of South Carolina
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.